Today: 9 November 2025
Subscribe
Browse Category

Biotech Stocks News 29 September 2025 - 3 November 2025

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Stock Performance and Recent Trend Axsome’s stock has been a standout performer in 2025. As of November 3, 2025, AXSM trades around $134–$135 per share, roughly doubling from its 52-week low of $75.56 finviz.com. The stock has gained about 60% year-to-date and 52% over the past year seattlepi.com – a remarkable run that far outpaces the broader biotech sector and the S&P 500. This surge reflects growing investor optimism as Axsome transforms into a commercial-stage company with multiple marketed drugs. Recent trading momentum: In the days leading up to Nov 3, AXSM shares climbed steadily, likely in anticipation of strong
3 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain investing.com. The prior day, RANI had closed at just $0.47, so the news sparked an almost threefold leap in value. In pre-market trading before the open, the stock had already jumped over +150%, and it continued to rally after the bell ts2.tech ts2.tech. By midday Oct. 17, shares were still
20 October 2025
 ·  ·  ·  ·  · 
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In

What to Know Before Markets Open on October 20, 2025 FDA Breakthrough News Ignites Rally Spruce Biosciences’ meteoric rise began with a game-changing regulatory win. On October 6, the company announced that the FDA had granted Breakthrough Therapy Designation (BTD) to its lead drug, tralesinidase alfa (TA-ERT) ts2.tech. TA-ERT is an experimental enzyme replacement therapy targeting Sanfilippo Syndrome Type B (also known as MPS IIIB) – a rare, inherited lysosomal storage disease that causes severe neurological decline in children stocktwits.com. The FDA’s BTD endorsement signals that early data for TA-ERT show “substantial improvement” over existing options for this deadly disease,
19 October 2025
 ·  ·  ·  ·  · 
Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets to speed drug discovery ts2.tech. In early October 2025 the stock showed wild swings: it plunged to the mid-$5s then rebounded ~16% on Oct 8 after an AI-focused tech conference and pipeline news ts2.tech ts2.tech. As of mid-day Oct 16, RXRX trades around $6.5, having closed at ~$6.79 on Oct 16 insidermonkey.com. This volatility reflects renewed investor interest in Recursion’s AI platform and upcoming trial readouts. Key Facts Recent Stock Performance Recursion’s share price has been unusually volatile in October
16 October 2025
 ·  ·  ·  ·  · 
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20 sec.gov. In VIRAGE, the oncolytic adenovirus VCN-01 is given with gemcitabine/nab‑paclitaxel standard chemotherapy. Interim abstract data (recently filed with the SEC) show that VCN-01 + chemotherapy substantially improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone sec.gov sec.gov. Patients receiving VCN-01 saw median OS up to
15 October 2025
 ·  ·  ·  · 
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist reuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeutics reuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration deal reuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early
10 October 2025
 ·  ·  ·  ·  · 
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells adaptimmune.com. Adaptimmune’s proprietary platform, known as SPEAR T-cells (Specific Peptide Enhanced Affinity Receptor), allows it to design TCRs that recognize tumor-specific antigens (such as MAGE-A4 or NY-ESO-1) and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to
9 October 2025
 ·  ·  ·  ·  · 
Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Sources: Company filings and press releases globenewswire.com stocktitan.net; financial media (Reuters, Investing.com, Stocktwits, Seeking Alpha) reuters.com stocktwits.com investing.com; market data services stocktitan.net tipranks.com. All figures and quotes are from cited reports.
29 September 2025
 ·  ·  ·  ·  ·  · 
Go toTop